title: Ifosfamide, carboplatin and etoposide for good prognosis small cell lung cancer: are four courses inadequate? West of Scotland Lung Cancer Group.
authors.forename: M Q
authors.initials: MQ
authors.lastname: Hatton
authors.forename: J
authors.initials: J
authors.lastname: Cassidy
authors.forename: S
authors.initials: S
authors.lastname: Bicknell
authors.forename: P
authors.initials: P
authors.lastname: Semple
authors.forename: B
authors.initials: B
authors.lastname: Stack
authors.forename: W P
authors.initials: WP
authors.lastname: Steward
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D016190:Carboplatin; D007069:Ifosfamide